Drugs / Vofopitant
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00907985 | May 2009 → Jun 2010 | bipolar disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00383786 | Sep 2006 → Jun 2009 | post-traumatic stress disorder | Baylor College of Medicine | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00606697 Comparator | Dec 2007 → May 2008 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vofopitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00907985 ↗ |
| Known as | GR-205171A | ChEMBL registry synonym — accepted as the source's own label CHEMBL522302 ↗ |
| Known as | GR205171 | “Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally.” NCT00907985 ↗ |
| Known as | VOFOPITANT DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL522302 ↗ |
| Action | Inhibit | “The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD.” PMID 21194898 ↗ Dec 20101“Neurokinin 1 receptor antagonist” CHEMBL522302 ↗ |
| Modality | Small molecule | — CHEMBL522302 ↗ |
| Route | Oral | “administered orally” NCT00907985 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL522302 ↗ |